Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

RECURSION PHARMACEUTICALS, INC. Stock Research

RXRX

7.97USD-0.16(-1.97%)Market Closed
Watchlist

Market Summary

USD7.97-0.16
Market Closed
-1.97%

RXRX Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

RXRX Stock Price

RXRX RSI Chart

RXRX Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-6.34

Price/Sales (Trailing)

32.96

Price/Free Cashflow

-6.21

RXRX Price/Sales (Trailing)

RXRX Profitability

Return on Equity

-57.84%

Return on Assets

-39.66%

Free Cashflow Yield

-16.11%

RXRX Fundamentals

RXRX Revenue

Revenue (TTM)

50.0M

Revenue Y/Y

43.56%

Revenue Q/Q

-9.21%

RXRX Earnings

Earnings (TTM)

-260.0M

Earnings Y/Y

-17.03%

Earnings Q/Q

-17.45%

Price Action

52 Week Range

16.75
(Low)(High)

Last 7 days

-7.3%

Last 30 days

-12.2%

Last 90 days

8.3%

Trailing 12 Months

-26.6%

RXRX Financial Health

Current Ratio

5.34

RXRX Investor Care

Shares Dilution (1Y)

20.05%

Diluted EPS (TTM)

-1.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for RXRX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Virani Shafique
acquired
39,960
2.22
18,000
chief business officer
2023-09-15
Gibson Christopher
gifted
-
-
-10,000
chief executive officer
2023-09-15
Gibson Christopher
acquired
-
-
10,000
chief executive officer
2023-09-15
Virani Shafique
sold
-155,880
8.66
-18,000
chief business officer
2023-09-13
Secora Michael
sold
-217,318
8.6927
-25,000
chief financial officer
2023-09-13
Secora Michael
acquired
83,250
2.22
37,500
chief financial officer
2023-09-12
Secora Michael
sold
-210,632
8.4253
-25,000
chief financial officer
2023-09-12
Secora Michael
acquired
83,250
2.22
37,500
chief financial officer
2023-09-06
Gibson Christopher
acquired
-
-
20,000
chief executive officer
2023-09-06
Gibson Christopher
sold
-8,836
8.8363
-1,000
chief executive officer

1–10 of 50

Which funds bought or sold RXRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
73.00
680
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
4.2
3,422
23,924
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
139,000
1,303,000
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
60.49
524,899
1,183,190
-%
2023-08-16
Nuveen Asset Management, LLC
added
9.76
1,568,570
8,408,570
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
7.91
744,218
4,313,520
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
27.81
254,994
846,142
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
unchanged
-
246,929
2,305,700
-%
2023-08-15
CENTAURUS FINANCIAL, INC.
added
20.13
25,000
99,000
0.01%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
reduced
-0.12
274,000
2,578,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying RXRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RXRX
No. of Funds

Schedule 13G FIlings of RECURSION PHARMACEUTICALS

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 22, 2023
kinnevik ab (publ)
5.6%
10,405,668
SC 13G
Feb 14, 2023
lux capital management, llc
3.3%
6,004,722
SC 13G/A
Feb 09, 2023
vanguard group inc
5.54%
10,057,363
SC 13G
Feb 03, 2023
blackrock inc.
5.9%
10,667,624
SC 13G
Jan 24, 2023
baillie gifford & co
13.66%
24,820,850
SC 13G/A
Oct 31, 2022
mubadala investment co pjsc
6.3%
11,291,937
SC 13D/A
Feb 14, 2022
data collective iv, l.p.
3.7%
5,941,120
SC 13G
Feb 14, 2022
lux capital management, llc
8.2%
13,021,519
SC 13G

Recent SEC filings of RECURSION PHARMACEUTICALS

View All Filings
Date Filed Form Type Document
Sep 21, 2023
4
Insider Trading
Sep 19, 2023
144
Notice of Insider Sale Intent
Sep 19, 2023
4
Insider Trading
Sep 19, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 14, 2023
4
Insider Trading
Sep 13, 2023
144
Notice of Insider Sale Intent
Sep 12, 2023
144
Notice of Insider Sale Intent
Sep 08, 2023
4
Insider Trading
Sep 07, 2023
4
Insider Trading

RECURSION PHARMACEUTICALS News

Seeking Alpha
Exscientia stock rises as Merck KGaA joins AI drug discovery ....
Seeking Alpha,
40 hours ago
Stocks Register
MarketBeat

Returns for RXRX

Cumulative Returns on RXRX

Risks for RXRX

What is the probability of a big loss on RXRX?

96.9%


Probability that RECURSION PHARMACEUTICALS stock will be more than 20% underwater in next one year

96.9%


Probability that RECURSION PHARMACEUTICALS stock will be more than 30% underwater in next one year.

86.7%


Probability that RECURSION PHARMACEUTICALS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RXRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if RECURSION PHARMACEUTICALS was unfortunately bought at previous high price.

Drawdowns

Financials for RECURSION PHARMACEUTICALS

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue7.2%49,98746,64439,84328,70018,07412,94910,17810,3368,82725,2213,9623,5513,1412,7302,319
Operating Expenses-------192,953153,732128,295103,22088,57780,40773,61273,61264,760
  S&GA Expenses8.5%90,49083,39981,59980,96277,16469,81957,68246,05537,32928,63425,25823,57921,44022,24418,951
  R&D Expenses9.8%186,553169,932155,696160,008152,418143,603135,271107,67790,96674,58663,31956,82852,17251,36845,809
Interest Expenses-3.7%52.0054.0055.0057.001684406808318079379891,0971,4441,224485
Net Income-4.5%-259,990-248,824-239,476-246,917-233,900-211,741-186,479-147,312-123,757-99,299-87,006-81,653-74,734-73,696-61,879
Net Income Margin100.0%--5.33*-6.01*-8.60*-10.38*-3.94*-18.32*-2.88*-2.49*------
Free Cashflow100.0%--272,120-120,583-133,478-113,428-75,195-198,412-127,904-105,432-117,048-74,821-74,821-71,668-74,004-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets6.3%667627701612673734610659699272299
  Current Assets-12.4%431492570482546619535601648222266
    Cash Equivalents-14.2%406473550455464518295405643219267
  Net PPE-0.3%90.0090.0088.0086.0082.0071.0065.0055.0049.0045.0026.00
  Goodwill7455.1%61.001.001.001.001.001.001.00---1.00
Liabilities0.3%19819721522323524167.0060.0056.0057.0057.00
  Current Liabilities23.7%11492.0010083.0097.0086.0047.0043.0030.0027.0023.00
Shareholder's Equity9.0%469430486388438494543599643--
  Retained Earnings-10.9%-781-704-639-582-521-456-400-335-287-244-213
  Additional Paid-In Capital10.2%1,2511,1351,12597095995094393493011.007.00
Shares Outstanding7.5%20719219117417217117016913823.0022.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-2.5%-240,072-234,228-83,524-99,934-78,441-50,471-158,614-88,883-75,291-58,337-45,399-71,962-69,032-71,268-57,042
  Share Based Compensation19.7%37,22731,09127,90924,55519,01118,65314,84211,6899,3964,8484,2924,1394,0685,0601,385
Cashflow From Investing-15.7%37,61244,605193,249148,985-97,872-109,024-271,744-224,092-33,645-27,472-8,740-5,532-1,446-2,736-3,910
Cashflow From Financing0.7%155,302154,183154,34510,885-2,547458,490458,540464,779705,595242,272246,135314,80012,75823,988120,410

RXRX Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue    
Revenue$ 11,017$ 7,674$ 23,151$ 13,007
Operating costs and expenses    
Cost of revenue9,38214,22721,82922,026
Research and development55,06038,439101,73770,880
General and administrative28,29021,19951,16542,273
Total operating costs and expenses92,73273,865174,731135,179
Loss from operations(81,715)(66,191)(151,580)(122,172)
Other income, net4,9896319,527633
Net loss$ (76,726)$ (65,560)$ (142,053)$ (121,539)
Per share data    
Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share)$ (0.38)$ (0.38)$ (0.71)$ (0.71)
Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share)$ (0.38)$ (0.38)$ (0.71)$ (0.71)
Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)201,415,475172,212,390198,957,804171,455,595
Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)201,415,475172,212,390198,957,804171,455,595
Operating revenue    
Revenue    
Revenue$ 11,016$ 7,653$ 23,150$ 12,952
Grant revenue    
Revenue    
Revenue$ 1$ 21$ 1$ 55

RXRX Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 405,870$ 549,912
Restricted cash3,3251,280
Other receivables3,0512,753
Other current assets18,77415,869
Total current assets431,020569,814
Restricted cash, non-current7,6297,920
Property and equipment, net89,76888,192
Operating lease right-of-use assets34,89933,255
Intangible assets, net42,7571,306
Goodwill60,516801
Other assets, non-current1100
Total assets666,699701,288
Current liabilities  
Accounts payable2,0864,586
Accrued expenses and other liabilities32,87332,904
Unearned revenue73,10556,726
Notes payable67697
Operating lease liabilities5,2195,952
Total current liabilities113,959100,265
Unearned revenue, non-current32,43670,261
Notes payable, non-current1,155536
Operating lease liabilities, non-current45,85044,420
Deferred tax liabilities4,3360
Total liabilities197,736215,482
Commitments and contingencies (Note 7)
Stockholders’ equity  
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of June 30, 2023 and December 31, 2022; 206,737,332 shares (Class A 195,051,012, Class B 7,679,871 and Exchangeable 4,006,449) and 191,022,864 shares (Class A 183,209,655, Class B 7,813,209 and Exchangeable 0) issued and outstanding as of June 30, 2023 and December 31, 2022, respectively22
Additional paid-in capital1,250,5701,125,360
Accumulated deficit(781,609)(639,556)
Total stockholders’ equity468,963485,806
Total liabilities and stockholders’ equity$ 666,699$ 701,288
Chistopher C. Gibson
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.